22:38 , Mar 19, 2019 |  BC Extra  |  Company News

Management tracks: Medicines Co., Mallinckrodt, ArQule

The Medicines Co. (NASDAQ:MDCO) terminated the employment of Christopher Cox, EVP and chief corporate development officer, effective March 15. Details were not disclosed. Mallinckrodt plc (NYSE:MNK) hired Bryan Reasons as CFO. He will succeed interim...
23:46 , Jan 15, 2019 |  BC Extra  |  Company News

Management tracks: Immunocore gains second ex-AZ exec

Immunocore Ltd. (Abingdon, U.K.) said it hired David Berman in September as head of R&D. Berman was SVP and head of immuno-oncology at AstraZeneca plc (LSE:AZN; NYSE:AZN), and before that was head of early stage...
20:06 , Oct 5, 2018 |  BC Week In Review  |  Financial News

ArunA raises $5.3M

ArunA Biomedical Inc. (Athens, Ga.) said it raised $5.3 million from existing undisclosed angel investors. ArunA’s neural exosome platform allows drugs and drug combinations to cross the blood brain barrier. The company announced in January...
22:04 , Jan 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Stroke Mouse studies suggest human neural stem cell (NSC)-derived extracellular vesicles could help treat stroke. In a mouse model of stroke, IV injection of NSC-derived extracellular vesicles decreased tissue loss and infarct size and...
19:27 , Jan 4, 2018 |  BC Innovations  |  Translation in Brief

ArunA’s exosome entrance

Stem cell manufacturer ArunA Biomedical Inc. has announced a pivot into the exosome therapeutic space, as well as publication of the first data showing its neural stem cell-derived exosomes and other extracellular vesicles are effective...
08:00 , Nov 23, 2009 |  BC Week In Review  |  Company News

Cytoo management update

Cytoo S.A. , Grenoble, France   Business: Microarrays, Supply/Service   Hired: William Sharp as president and CEO for Cytoo's Cytoo Inc. U.S. subsidiary, formerly president and CEO of ArunA Biomedical Inc.  ...
07:00 , Aug 25, 2008 |  BC Week In Review  |  Company News

ArunA Biomedical Inc., University of Georgia Research Foundation deal

ArunA received an exclusive, worldwide license to develop and commercialize the university’s human mesenchymal cells (hMSC) derived from human embryonic stem cells (hESC) for undisclosed purposes. ArunA plans to offer hMSC kits in multiple formats...
07:00 , Aug 4, 2008 |  BC Week In Review  |  Company News

ArunA Biomedical Inc. management update

ArunA Biomedical Inc. , Athens, Ga.   Business: Gene/Cell therapy   Hired: William Sharp as president, CEO and a director, formerly CCO of BioProcessors Corp. ; he replaces Steven Stice, who will remain chairman and...
07:00 , Mar 19, 2007 |  BC Week In Review  |  Company News

Aruna Biomedical Inc., Millipore sales and marketing update

Aruna granted MIL an exclusive worldwide license to market and distribute a cell line of human neural progenitor cells and optimized media for neural research. The cells, which are derived from NIH-registered human embryonic stem...
08:00 , Jan 29, 2007 |  BC Week In Review  |  Company News

Aruna Biomedical Inc., University of Georgia Research Foundation deal

Aruna received exclusive worldwide rights to develop and commercialize the university's neural cells derived from human embryonic stem cells (hESCs) for research purposes. Aruna plans to launch human neural progenitor cells early this year and...